First bulk wholesale deal for MMJ Phytotech
Published 19-NOV-2015 10:52 A.M.
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MMJ Phytotech (ASX:MMJ) has bagged its first wholesale sale of its Satipharm CBD pill, a sale which could open doors for the pharmaceutical player.
It told the market today that it had secured a $225,000 sale to UK supplement distributor Prima Sport, with the pill to be sold through a dedicated portal on the Prima Sport website.
MMJ said it expects the order to be sold to customers within the first half of next year and it was in discussions with other European companies about doing a similar deal.
“This partnership with Prima Sport, a leading supplement distributor, provides MMJ with access to a larger market within the United Kingdom and has the potential to raise further awareness of our CBD capsules,” MMJ managing director Andreas Gedeon said.
“This agreement also opens up further opportunities with Prima Sport and other distributors to wholesale further products and accelerate our wholesale strategy.”
MMJ first bagged a sale of its CBD pill back at the end of August, but this was from its own website rather than a wholesale bulk deal.
MMJ has also recently signalled that it intends to pursue a market entry in Australia on the back of regulatory wins in several states.
The pharmaceutical company raised $2 million to fund the market entry, but further bulk wholesale deals could provide a step-change in revenue for the company and fund further entries or acquisitions.
About MMJ Phytotech
The ‘farm to pharma’ company grows cannabis plants in Canada to extract the vital medicinal ingredients from the plant.
It then sends them off to Switzerland, where its subsidiary Satipharm develops products such as the CBD pill from them.
It also has its eyes on being a pharmaceutical developer and distributor of cannabinoid “Active Pharmaceutical Ingredients” (APIs), which are highly valuable and for cannabinoid (CBD), can be traded at prices upwards of $350,000 per kilogram.
It also has a R&D offshoot in Israel which works on research and product development.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.